Recent Updates — EUDA

EUDA Health Holdings Limited filed its unaudited interim financial results for the six months ended June 30, 2026. The company reported a net loss of $795,004, narrowing from $1,204,001 in the prior year period, driven by a 13.4% revenue increase to $3,467,835 and improved gross margins in its holistic wellness segment. Total revenues rose due to an 8.0% increase in property management services to $2,255,161 and a 35.7% surge in holistic wellness consumer products and services to $1,212,674. The company also executed a register direct offering raising $3.75 million and issued shares for crypto assets valued at $7.31 million. EUDA Health Holdings Limited operates in the health and wellness sector, providing property management and holistic wellness consumer products and services.

EUDA Health Holdings Limited signed a tri-party Memorandum of Understanding with GO POSB Organoids and Shenzhen Innovation Immunotechnology to collaborate on the development, manufacturing, and commercialization of next-generation off-the-shelf oncology cell therapies derived from induced pluripotent stem cells. The agreement aims to advance treatments for cancer and wellness applications. EUDA Health Holdings Limited is a Singapore-based distributor of third-party wellness and non-invasive healthcare products and services in Asia, with a focus on Singapore, Malaysia, and China, and also operates a property management business.

EUDA Health Holdings Limited has suspended and subsequently will terminate the At The Market Offering Agreement with Chardan Capital Markets LLC, effective July 22, 2026. The company has suspended the equity offering of up to $10,000,000 in ordinary shares through the commission-based broker-dealerer than Charadan. No ordinary shares have been sold under theing the ATM Offering. EUDA Health Holdings Limited is a healthcare technology company that provides digital health solutions.